BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26616737)

  • 1. Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting.
    Lukas RV; Wainwright DA; Laterra JJ
    Future Oncol; 2016 Jan; 12(2):143-7. PubMed ID: 26616737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuro-oncology: a selected review of ASCO 2016 abstracts.
    Chamberlain MC
    CNS Oncol; 2016 Oct; 5(4):193-8. PubMed ID: 27616612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.
    Wen PY
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1367-9. PubMed ID: 20836670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting report: human fetal tissue transplantation research panel.
    Barnes DW; Stevenson RE
    In Vitro Cell Dev Biol; 1989 Jan; 25(1):6-8. PubMed ID: 2914816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuro-oncology: a selected review of ASCO 2012 abstracts.
    Chamberlain MC
    CNS Oncol; 2012 Nov; 1(2):127-30. PubMed ID: 25057862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary brain tumors, delta 24 and tumor metabolism. Interview by Rona Williamson.
    Gilbert MR
    Expert Rev Neurother; 2013 Apr; 13(4):353-5. PubMed ID: 23545051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in brain metastases presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part I.
    Chen LF; Patel JD; Lukas RV
    Future Oncol; 2016 Nov; 12(22):2535-2538. PubMed ID: 27595336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in brain metastases presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part II.
    Chen LF; Patel JD; Lukas RV
    Future Oncol; 2016 Dec; 12(23):2669-2672. PubMed ID: 27605123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies.
    Khan-Farooqi HR; Prins RM; Liau LM
    Neurol Res; 2005 Oct; 27(7):692-702. PubMed ID: 16197806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.
    Lukas RV; Mehta MP; Lesniak MS
    Neurooncol Pract; 2015 Jun; 2(2):57-61. PubMed ID: 27621837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for high-grade glioma.
    Dixit S
    Future Oncol; 2014 May; 10(6):911-5. PubMed ID: 24941977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interview: Professor Andrew Feinberg speaks to Epigenomics.
    Feinberg A
    Epigenomics; 2009 Oct; 1(1):25-7. PubMed ID: 22122634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Alsamarai S; Libutti SK; Saif MW
    JOP; 2010 Jul; 11(4):336-40. PubMed ID: 20601807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO).
    Chamberlain MC
    CNS Oncol; 2016 Jul; 5(3):115-9. PubMed ID: 27230972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Association for Cancer Research: potential target antigens for cancer immunotherapy. April 1-5, 2000, San Francisco, CA, USA.
    Shankar G
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1419-24. PubMed ID: 11203451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
    Templeton AJ; Dutoit V; Cathomas R; Rothermundt C; Bärtschi D; Dröge C; Gautschi O; Borner M; Fechter E; Stenner F; Winterhalder R; Müller B; Schiess R; Wild PJ; Rüschoff JH; Thalmann G; Dietrich PY; Aebersold R; Klingbiel D; Gillessen S;
    Eur Urol; 2013 Jul; 64(1):150-8. PubMed ID: 23582881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology--35th annual meeting. 15-18 May 1999, Atlanta, GA, USA.
    Boven E
    IDrugs; 1999 Jul; 2(7):617-9. PubMed ID: 16127623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.